Flagship and GSK announce a strategic collaboration to discover and develop a portfolio of novel medicines and vaccines, starting in respiratory and immunology. Read the full announcement about our latest Innovation Supply Chain Partnership which will leverage GSK’s disease expertise and development capability together with Flagship’s ecosystem of pioneering bioplatforms: https://bit.ly/4d0aed8
Flagship Pioneering
Biotechnology Research
Cambridge, MA 96,328 followers
We are a biotechnology company that invents and builds platform companies that change the world.
About us
Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.
- Website
-
http://www.flagshippioneering.com
External link for Flagship Pioneering
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Founded
- 2000
- Specialties
- life sciences, biotech, therapeutics, diagnostics, sustainability, climate change, artificial intelligence, machine learning, agtech, medicines, therapeutics, biology, entrepreneurship, biotechnology, science, innovation, and ventures
Locations
-
Primary
55 Cambridge Parkway
Suite 800E
Cambridge, MA 02142, US
Employees at Flagship Pioneering
-
Karim Lakhani
Professor Harvard Business School | Chair D^3 Institute at Harvard | Board Member, Mozilla Corporation & VideaHealth | Academic Partner, Flagship…
-
Venu Nagali
Strategy, Business Development & Finance Executive ✦ Increase Enterprise Value through Innovative Strategies and Building Results-Producing Teams
-
Susan Vidal
Strategic HR Leader & Employee Retention Evangelist
-
David Khougazian
Growth Partner at Flagship Pioneering
Updates
-
Flagship welcomes Raj Panjabi as Senior Partner to lead Flagship’s Preemptive Health and Medicine Initiative, which is pioneering a new field to protect, maintain, or improve people’s health before they get sick. Read the full announcement: https://bit.ly/4dz0Mxk
-
#FlagshipFounded CIBO Technologies announces a strategic partnership with Parcel.ag to help farmers in the US secure new income streams and advance regenerative agriculture.
CIBO and Parcel.ag have joined forces to empower U.S. farmers with new income streams and promote #RegenerativeAgriculture. Together, we're making sustainability incentives more accessible. #SustainableFarming #RegenerativeAg https://ow.ly/f6lv50SR7EK
-
-
Congratulations to the team at #FlagshipFounded ProFound Therapeutics on being recognized by Fierce Biotech as a #Fierce15 company. Learn what’s ahead for ProFound as it pioneers the discovery of previously unknown proteins to develop new medicines in the CEO Chat with John Lepore: https://bit.ly/3Sf88xR
We’re thrilled to announce Fierce Biotech has selected us as a 2024 #Fierce15 #biotech company! This year, we have rapidly advanced our ProFoundry™ Platform, most recently showcased by our exploration agreement with Pfizer and Pioneering Medicines to uncover novel potential treatments for #obesity. Learn more about how our team is pioneering the #ExpandedProteome, identifying novel proteins with the possibility to bring new therapeutic options to patients: https://lnkd.in/egAAqe6D
-
-
Hear from Sabrina Yang, Flagship Senior Principal and Chief Innovation Officer at #FlagshipFounded Empress Therapeutics, on how Empress is bringing certainty and speed to drug discovery by applying the power of genetics to source chemistry from inside the human body in this episode of The Bio Report podcast from Levine Media Group with Daniel Levine: https://lnkd.in/dSkDUgBr
New podcast episode just dropped 🎧! Empress Cofounder and Chief Innovation Officer Sabrina Yang discusses how the human body is an untapped hunting ground for new medicines. The biosynthetic genes in our metagenome are equivalent in size to roughly 50% of the human genome. That's about a meter of non-human genetic DNA inside of us waiting to be decoded and turned into potential medicines. She explains how the #Chemilogics platform can “read” the DNA code and use #AI to predict genes that are most likely to encode small molecules that play a causal role in health and disease. Empress then recodes these genes using synthetic biology, engineering microbes to produce compounds to create new small molecules with the potential to treat many diseases and disorders. 🎙️Listen to her full interview on the #BioReport #podcast with Daniel Levine: https://lnkd.in/dSkDUgBr #Chemilogics #smallmolecule #drugdiscovery #AI #machinelearning #microbiome #drugdiscovery
-
-
Flagship Pioneering reposted this
Curious about how #AI is shaping the future of drug discovery? Don’t miss our CEO Michael Nally’s interview with Brad Loncar on BiotechTV at the AI x Bio Summit at the NYSE. Mike shares exciting updates on our clinical programs, including our COVID-19 antibody and anti-TSLP molecule. Discover how we’re leveraging AI to build de novo proteins and reach historically undruggable targets. “By programming biology, we’re transforming drug discovery and creating better medicines faster." Learn more about the future of biotech in this compelling conversation. Check out the full interview: https://lnkd.in/gPFP2yEK #ProteinEngineering | #GenerativeAI
𝐀𝐈 𝐱 𝐁𝐢𝐨 𝐒𝐮𝐦𝐦𝐢𝐭: Generate:Biomedicines' CEO Michael Nally gives an update on the company's clinical and emerging programs. He describes clinical programs targeting COVID and TSLP, as well as emerging programs in the ADC space, TL1A, IL13, and more. Full video: https://lnkd.in/gPFP2yEK BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
“There’s no question that these fields are going to be essentially cooperating, not just coexisting...and the output is a lot of impact and value.” Hear Flagship Founder & CEO Noubar Afeyan discuss how biology and digital are increasingly interconnected and read about our new partnership with Analog Devices to accelerate the development of a fully digitized biological world: https://bit.ly/46gim6N
Today we announced a new strategic partnership with Flagship Pioneering that aims to leverage complementary expertise in applied biology and engineering to create and enhance multiple digital biology platform companies. During their discussion at our General Technical Conference, ADI’s Vincent Roche and Flagship’s Noubar Afeyan outline the importance of collaboration to help enable breakthrough solutions for human health and sustainability. See what they had to say. 👇
-
Meet Olivia Viessmann, Flagship Principal Machine Learning Scientist on the Pioneering Intelligence team! Tune in to hear her recite a poem by Harry Baker 🐝 that reflects the pioneering spirit at Flagship and share unique hobbies that keep her busy outside of the office in our new ⏰Off the Clock⏰ series. #WeAreFlagship 💼 Interested in joining the Flagship team? View our open roles: https://lnkd.in/ehVMz73f
-
“I think we’re at another time in history when we’ll look back in 10-15 years at a revolution in the making.” Hari Pujar, Flagship Operating Partner and COO of #FlagshipFounded Tessera Therapeutics, spoke at the American Association of Pharmaceutical Scientists (AAPS) | @aapscomms National Biotechnology Conference and shared how he sees a new era of innovation, Flagship’s company creation process, and how Tessera is pioneering Gene Writing™ to treat diseases at their source: https://lnkd.in/eUZWNrYw
-
Congrats to CFO of #FlagshipFounded Generate:Biomedicines Jason Silvers on being recognized at Boston Business Journal’s 2024 CFO of the Year awards.
Last week, Jason Silvers, our CFO, was recognized at the Boston Business Journal's 2024 CFO of the Year awards. This accolade honors chief financial officers who have significantly impacted their organizations and the broader economy. In an interview with the Boston Business Journal, Jason discusses his career shifts from medicine to law to finance. He highlights how these experiences have equipped him to lead our financial strategies effectively, particularly in challenging market conditions. The interview offers a glimpse into his professional perspective and decision-making process. Don't miss the full interview 👇 #TeamGenerate | #AudaciouslyAmbitious
Jason Silvers - Boston Business Journal
bizjournals.com